These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 9051159)
1. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Rossi A; Mancini F; Stratta P; Mattei P; Gismondi R; Pozzi F; Casacchia M Acta Psychiatr Scand; 1997 Jan; 95(1):40-3. PubMed ID: 9051159 [TBL] [Abstract][Full Text] [Related]
2. The effect of risperidone on cognition in patients with schizophrenia. Stip E; Lussier I Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249 [TBL] [Abstract][Full Text] [Related]
3. Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. Borkowska A; Araszkiewicz A; Rajewski A; Rybakowski JK Neuropsychobiology; 2002; 46(2):85-9. PubMed ID: 12378125 [TBL] [Abstract][Full Text] [Related]
4. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731 [TBL] [Abstract][Full Text] [Related]
5. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Lee SM; Chou YH; Li MH; Wan FJ; Yen MH Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386 [TBL] [Abstract][Full Text] [Related]
6. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427 [TBL] [Abstract][Full Text] [Related]
7. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Harvey PD; Rabinowitz J; Eerdekens M; Davidson M Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835 [TBL] [Abstract][Full Text] [Related]
9. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Harvey PD; Napolitano JA; Mao L; Gharabawi G Int J Geriatr Psychiatry; 2003 Sep; 18(9):820-9. PubMed ID: 12949850 [TBL] [Abstract][Full Text] [Related]
10. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Rémillard S; Pourcher E; Cohen H Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371 [TBL] [Abstract][Full Text] [Related]
12. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. Lipkovich IA; Deberdt W; Csernansky JG; Sabbe B; Keefe RS; Kollack-Walker S BMC Psychiatry; 2009 Jul; 9():44. PubMed ID: 19602273 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600 [TBL] [Abstract][Full Text] [Related]
15. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844 [TBL] [Abstract][Full Text] [Related]
16. Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone. Remberk B; Namysłowska I; Rybakowski F Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):348-54. PubMed ID: 22819848 [TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227 [TBL] [Abstract][Full Text] [Related]
18. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461 [TBL] [Abstract][Full Text] [Related]
19. Food and Drug Administration commentary on methodological issues in negative symptom trials. Laughren T; Levin R Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124 [No Abstract] [Full Text] [Related]
20. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]